Headlight Therapists & Psychiatric Services San Diego
5060 Shoreham Place, Suite 230 & 330, San Diego
4.0(208 Google reviews)
United States
13 listed treatment centers serving San Diego and the surrounding area.
5060 Shoreham Place, Suite 230 & 330, San Diego
4.0(208 Google reviews)
3252 Holiday Court, 112, San Diego
4.7(66 Google reviews)
462 Stevens Avenue, Suite 206, Solana Beach
5.0(63 Google reviews)
3530 Camino Del Rio North, 200, San Diego
5.0(33 Google reviews)
16476 Bernardo Center Drive, Suite 200, San Diego
5.0(27 Google reviews)
11515 El Camino Real, 100, San Diego
Every dose is given in a certified healthcare setting, followed by at least two hours of monitoring. Arrange transportation home after each visit. Distances below are straight-line miles from San Diego.
7.7 miles away · Chula Vista
10 miles away · Chula Vista
1061 Tierra Del Rey, Suite 200, Chula Vista
3.4(82 Google reviews)
12.1 miles away · Chula Vista
2300 Boswell Road, 275, Chula Vista
4.8(9 Google reviews)
12.1 miles away · Chula Vista
2300 Boswell Road, 275, Chula Vista
4.7(11 Google reviews)
12.1 miles away · Chula Vista
2300 Boswell Road, Suite 275, Chula Vista
4.6(204 Google reviews)
12.4 miles away · Chula Vista
900 Lane Avenue, 114, Chula Vista
4.4(18 Google reviews)
For people in San Diego considering SPRAVATO®, the most useful cost estimate is one based on your insurance benefits and the treatment center’s billing practices. Both the medication and the supervised treatment visit, including monitoring, may be billed. Ask for an estimate that accounts for both rather than the medication alone.
Prior authorization is common. Your insurer may require documentation of earlier antidepressant trials before deciding whether to authorize treatment. Ask the center which records it needs from previous prescribers and who will submit the request. Getting those records together early may help avoid missing information, but it does not guarantee approval.
Medicare coverage may fall under Part B or Part D, depending on the plan and treatment setting. California’s Medicaid program may also cover treatment, depending on the plan and setting. Do not assume that a directory listing means a center accepts either program; confirm directly with the center and your insurer.
Manufacturer savings programs exist for eligible commercially insured patients, not people using government insurance. Eligibility rules apply, and assistance should not be assumed to cover every treatment-related charge. Ask about current terms before relying on it.
Before starting, ask:
SPRAVATO® treatment takes place only in a healthcare setting certified through the SPRAVATO® REMS program. You administer the nasal spray yourself under a healthcare provider’s direct observation; it is never sent home with you. Certification is not confirmed in the supplied directory records, so verify it directly before scheduling.
For treatment-resistant depression, the typical labeled schedule starts with twice-weekly treatment during weeks 1–4, followed by weekly visits during weeks 5–8. Maintenance may be weekly or every two weeks. Your prescriber determines the schedule for your situation; do not assume that visits will become less frequent on a fixed date.
Set aside more than two hours for an appointment. Monitoring alone lasts at least two hours after each dose, and check-in, preparation, or additional observation can add time. Ask the center what appointment window to reserve before arranging work leave or caregiving coverage.
You need someone else to drive you home. You must not drive or operate machinery until the next day after a restful sleep. Arrange a dependable ride for every appointment and a backup if your driver cancels. If considering a hired ride, ask the center about its discharge and accompaniment requirements beforehand.
If you cannot find a listed San Diego center, or local listings do not meet your needs, broaden your search to listed locations such as Chula Vista, La Mesa, National City, or Solana Beach. Confirm certification, appointment availability, and insurance arrangements directly. Consider whether you can sustain the round-trip transportation and time away from work throughout treatment.
Use the directory as a starting point, then ask the center to confirm that its treatment location is certified through the SPRAVATO® REMS program. Certification is not confirmed in the supplied listing records. Also ask whether it is accepting new patients, how evaluations are scheduled, and whether it can accommodate your transportation needs. A listing does not establish insurance participation.
Spravato is approved for adults with treatment-resistant depression, either alone or with an oral antidepressant. It is also approved for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior, together with an oral antidepressant. It is not approved for children. A clinician must review your symptoms, treatment history, and health risks to decide whether it is appropriate for you.
Coverage depends on your plan and the treatment setting. Prior authorization and records of previous antidepressant trials are commonly required. Ask your insurer about both the medication and the monitored visit, including network status and your share of costs. Medicare and California Medicaid coverage also depend on the plan and setting; confirm coverage and the center’s participation rather than assuming either from a listing.
You self-administer the nasal spray under direct observation in a REMS-certified healthcare setting. After the dose, staff monitor you for at least two hours for effects such as sedation, dissociation, breathing problems, and increased blood pressure. The full appointment may take longer. Arrange a ride home, and do not drive or operate machinery until the next day after a restful sleep.
Ask about sedation, dissociation—feeling disconnected from yourself or your surroundings—breathing problems, and blood pressure increases. Spravato carries boxed warnings for sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviors. It is a Schedule III controlled substance. Review your health history and medicines with the clinician, and tell staff promptly if you feel unwell during observation.
No. Spravato has not been shown to prevent suicide or reduce suicidal thoughts or behavior, and it does not replace hospitalization when needed. Its approval for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior requires use with an oral antidepressant. If you are in crisis, call or text 988. If there is immediate danger or a medical emergency, call 911 rather than waiting for an appointment.
Approved uses, nearby treatment centers, and medically sourced patient guides.